Exploratory trial of a combination therapy of Gemcitabine and immunotherapy against pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Gemcitabine (Primary) ; WT1-W10 peptide vaccine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 19 Feb 2018 Status changed from active, no longer recruiting to completed.
- 22 Feb 2017 New trial record